Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India
Identifieur interne : 000401 ( PascalFrancis/Corpus ); précédent : 000400; suivant : 000402Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India
Auteurs : J. Yuvaraj ; S. P. Pani ; P. Vanamail ; K. D. Ramaiah ; P. K. DasSource :
- TM & IH. Tropical medicine & international health [ 1360-2276 ] ; 2008.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
OBJECTIVE To evaluate the impact of seven rounds of mass administration of diethylcarbamazine (DEC) and ivermectin on the prevalence of chronic lymphatic filariasis and to compare it with that observed in a placebo arm in a community-level trial. METHODS Cross-sectional clinical surveys were carried out before and after seven rounds of mass drug administration (MDA). About 54-75% of the target population were treated at each round of MDA. RESULTS After seven rounds, the hydrocele prevalence had declined from the pre-intervention level of 20.5-5.1% (P < 0.05) in the DEC arm, from 23.9% to 10.4% (P < 0.05) in the ivermectin arm and from 20.4% to 10.9% (P < 0.05) in the placebo arm, equivalent to reductions of 75.3%, 56.6% and 46.6%, respectively. The lymphoedema/elephantiasis prevalence declined only marginally and without statistical significance from 3.7% to 3.2%, 4.6% to 3.9% and 2.9% to 2.3% in the DEC, ivermectin and placebo arm. After the seventh MDA, none of the sampled people in the 0-20 age group was found with hydrocele and there was a statistically significant decline in hydrocele prevalence in all other age groups in the communities treated with DEC, the drug known to have macrofilaricidal effect. The impact was relatively less in ivermectin arm. CONCLUSION Repeated DEC administration has the potential to prevent incidence of new hydrocele cases and may resolve the manifestation at least in a proportion of affected people. Apart from reducing the microfilaraemia prevalence and transmission of infection, MDA also results in significant public health benefits by reducing the burden of hydrocele in treated communities.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 08-0227645 INIST |
|---|---|
| ET : | Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India |
| AU : | YUVARAJ (J.); PANI (S. P.); VANAMAIL (P.); RAMAIAH (K. D.); DAS (P. K.) |
| AF : | Vector Control Research Centre/Pondicherry/Inde (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | TM & IH. Tropical medicine & international health; ISSN 1360-2276; Royaume-Uni; Da. 2008; Vol. 13; No. 5; Pp. 737-742; Bibl. 1/2 p. |
| LA : | Anglais |
| EA : | OBJECTIVE To evaluate the impact of seven rounds of mass administration of diethylcarbamazine (DEC) and ivermectin on the prevalence of chronic lymphatic filariasis and to compare it with that observed in a placebo arm in a community-level trial. METHODS Cross-sectional clinical surveys were carried out before and after seven rounds of mass drug administration (MDA). About 54-75% of the target population were treated at each round of MDA. RESULTS After seven rounds, the hydrocele prevalence had declined from the pre-intervention level of 20.5-5.1% (P < 0.05) in the DEC arm, from 23.9% to 10.4% (P < 0.05) in the ivermectin arm and from 20.4% to 10.9% (P < 0.05) in the placebo arm, equivalent to reductions of 75.3%, 56.6% and 46.6%, respectively. The lymphoedema/elephantiasis prevalence declined only marginally and without statistical significance from 3.7% to 3.2%, 4.6% to 3.9% and 2.9% to 2.3% in the DEC, ivermectin and placebo arm. After the seventh MDA, none of the sampled people in the 0-20 age group was found with hydrocele and there was a statistically significant decline in hydrocele prevalence in all other age groups in the communities treated with DEC, the drug known to have macrofilaricidal effect. The impact was relatively less in ivermectin arm. CONCLUSION Repeated DEC administration has the potential to prevent incidence of new hydrocele cases and may resolve the manifestation at least in a proportion of affected people. Apart from reducing the microfilaraemia prevalence and transmission of infection, MDA also results in significant public health benefits by reducing the burden of hydrocele in treated communities. |
| CC : | 002B01; 002B05E03B4D; 002B12B04 |
| FD : | Diéthylcarbamazine; Ivermectine; Filariose lymphatique; Maladie chronique; Lymphoedème; Hydrocèle; Campagne de masse; Prévalence; Chronique; Sud; Inde; Médicament; Médecine tropicale; Antiparasitaire; Anthelminthique; Epanchement |
| FG : | Nématodose; Helminthiase; Parasitose; Infection; Asie; Lactone; Macrocycle; Pathologie des vaisseaux lymphatiques; Pathologie de l'appareil circulatoire; Pathologie de l'appareil génital mâle; Pathologie du testicule |
| ED : | Diethylcarbamazine; Ivermectin; Lymphatic filariasis; Chronic disease; Lymphedema; Hydrocele; Mass campaign; Prevalence; Chronic; South; India; Drug; Tropical medicine; Parasiticide; Anthelmintic; Effusion |
| EG : | Nematode disease; Helminthiasis; Parasitosis; Infection; Asia; Lactone; Macrocycle; Lymphatic vessel disease; Cardiovascular disease; Male genital diseases; Testicular diseases |
| SD : | Dietilcarbamazina; Ivermectina; Filariasis linfática; Enfermedad crónica; Linfedema; Hidrocele; Campaña de población; Prevalencia; Crónico; Sur; India; Medicamento; Medicina tropical; Antiparasitario; Antihelmíntico; Derrame |
| LO : | INIST-26295.354000172757520170 |
| ID : | 08-0227645 |
Links to Exploration step
Pascal:08-0227645Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India</title><author><name sortKey="Yuvaraj, J" sort="Yuvaraj, J" uniqKey="Yuvaraj J" first="J." last="Yuvaraj">J. Yuvaraj</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S. P." last="Pani">S. P. Pani</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P." last="Vanamail">P. Vanamail</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K. D." last="Ramaiah">K. D. Ramaiah</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P. K." last="Das">P. K. Das</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">08-0227645</idno><date when="2008">2008</date><idno type="stanalyst">PASCAL 08-0227645 INIST</idno><idno type="RBID">Pascal:08-0227645</idno><idno type="wicri:Area/PascalFrancis/Corpus">000401</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India</title><author><name sortKey="Yuvaraj, J" sort="Yuvaraj, J" uniqKey="Yuvaraj J" first="J." last="Yuvaraj">J. Yuvaraj</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S. P." last="Pani">S. P. Pani</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P." last="Vanamail">P. Vanamail</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Ramaiah, K D" sort="Ramaiah, K D" uniqKey="Ramaiah K" first="K. D." last="Ramaiah">K. D. Ramaiah</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Das, P K" sort="Das, P K" uniqKey="Das P" first="P. K." last="Das">P. K. Das</name><affiliation><inist:fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">TM & IH. Tropical medicine & international health</title><title level="j" type="abbreviated">TM IH, Trop. med. int. health</title><idno type="ISSN">1360-2276</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">TM & IH. Tropical medicine & international health</title><title level="j" type="abbreviated">TM IH, Trop. med. int. health</title><idno type="ISSN">1360-2276</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Anthelmintic</term><term>Chronic</term><term>Chronic disease</term><term>Diethylcarbamazine</term><term>Drug</term><term>Effusion</term><term>Hydrocele</term><term>India</term><term>Ivermectin</term><term>Lymphatic filariasis</term><term>Lymphedema</term><term>Mass campaign</term><term>Parasiticide</term><term>Prevalence</term><term>South</term><term>Tropical medicine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Ivermectine</term><term>Filariose lymphatique</term><term>Maladie chronique</term><term>Lymphoedème</term><term>Hydrocèle</term><term>Campagne de masse</term><term>Prévalence</term><term>Chronique</term><term>Sud</term><term>Inde</term><term>Médicament</term><term>Médecine tropicale</term><term>Antiparasitaire</term><term>Anthelminthique</term><term>Epanchement</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">OBJECTIVE To evaluate the impact of seven rounds of mass administration of diethylcarbamazine (DEC) and ivermectin on the prevalence of chronic lymphatic filariasis and to compare it with that observed in a placebo arm in a community-level trial. METHODS Cross-sectional clinical surveys were carried out before and after seven rounds of mass drug administration (MDA). About 54-75% of the target population were treated at each round of MDA. RESULTS After seven rounds, the hydrocele prevalence had declined from the pre-intervention level of 20.5-5.1% (P < 0.05) in the DEC arm, from 23.9% to 10.4% (P < 0.05) in the ivermectin arm and from 20.4% to 10.9% (P < 0.05) in the placebo arm, equivalent to reductions of 75.3%, 56.6% and 46.6%, respectively. The lymphoedema/elephantiasis prevalence declined only marginally and without statistical significance from 3.7% to 3.2%, 4.6% to 3.9% and 2.9% to 2.3% in the DEC, ivermectin and placebo arm. After the seventh MDA, none of the sampled people in the 0-20 age group was found with hydrocele and there was a statistically significant decline in hydrocele prevalence in all other age groups in the communities treated with DEC, the drug known to have macrofilaricidal effect. The impact was relatively less in ivermectin arm. CONCLUSION Repeated DEC administration has the potential to prevent incidence of new hydrocele cases and may resolve the manifestation at least in a proportion of affected people. Apart from reducing the microfilaraemia prevalence and transmission of infection, MDA also results in significant public health benefits by reducing the burden of hydrocele in treated communities.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1360-2276</s0></fA01><fA03 i2="1"><s0>TM IH, Trop. med. int. health</s0></fA03><fA05><s2>13</s2></fA05><fA06><s2>5</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India</s1></fA08><fA11 i1="01" i2="1"><s1>YUVARAJ (J.)</s1></fA11><fA11 i1="02" i2="1"><s1>PANI (S. P.)</s1></fA11><fA11 i1="03" i2="1"><s1>VANAMAIL (P.)</s1></fA11><fA11 i1="04" i2="1"><s1>RAMAIAH (K. D.)</s1></fA11><fA11 i1="05" i2="1"><s1>DAS (P. K.)</s1></fA11><fA14 i1="01"><s1>Vector Control Research Centre</s1><s2>Pondicherry</s2><s3>IND</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ></fA14><fA20><s1>737-742</s1></fA20><fA21><s1>2008</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>26295</s2><s5>354000172757520170</s5></fA43><fA44><s0>0000</s0><s1>© 2008 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1/2 p.</s0></fA45><fA47 i1="01" i2="1"><s0>08-0227645</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>TM & IH. Tropical medicine & international health</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>OBJECTIVE To evaluate the impact of seven rounds of mass administration of diethylcarbamazine (DEC) and ivermectin on the prevalence of chronic lymphatic filariasis and to compare it with that observed in a placebo arm in a community-level trial. METHODS Cross-sectional clinical surveys were carried out before and after seven rounds of mass drug administration (MDA). About 54-75% of the target population were treated at each round of MDA. RESULTS After seven rounds, the hydrocele prevalence had declined from the pre-intervention level of 20.5-5.1% (P < 0.05) in the DEC arm, from 23.9% to 10.4% (P < 0.05) in the ivermectin arm and from 20.4% to 10.9% (P < 0.05) in the placebo arm, equivalent to reductions of 75.3%, 56.6% and 46.6%, respectively. The lymphoedema/elephantiasis prevalence declined only marginally and without statistical significance from 3.7% to 3.2%, 4.6% to 3.9% and 2.9% to 2.3% in the DEC, ivermectin and placebo arm. After the seventh MDA, none of the sampled people in the 0-20 age group was found with hydrocele and there was a statistically significant decline in hydrocele prevalence in all other age groups in the communities treated with DEC, the drug known to have macrofilaricidal effect. The impact was relatively less in ivermectin arm. CONCLUSION Repeated DEC administration has the potential to prevent incidence of new hydrocele cases and may resolve the manifestation at least in a proportion of affected people. Apart from reducing the microfilaraemia prevalence and transmission of infection, MDA also results in significant public health benefits by reducing the burden of hydrocele in treated communities.</s0></fC01><fC02 i1="01" i2="X"><s0>002B01</s0></fC02><fC02 i1="02" i2="X"><s0>002B05E03B4D</s0></fC02><fC02 i1="03" i2="X"><s0>002B12B04</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Diéthylcarbamazine</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Diethylcarbamazine</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Dietilcarbamazina</s0><s2>NK</s2><s2>FR</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Ivermectine</s0><s2>NK</s2><s2>FR</s2><s2>FF</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Ivermectin</s0><s2>NK</s2><s2>FR</s2><s2>FF</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Ivermectina</s0><s2>NK</s2><s2>FR</s2><s2>FF</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Filariose lymphatique</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Lymphatic filariasis</s0><s5>03</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Filariasis linfática</s0><s5>03</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Maladie chronique</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Chronic disease</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Enfermedad crónica</s0><s2>NM</s2><s5>04</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Lymphoedème</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Lymphedema</s0><s5>05</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Linfedema</s0><s5>05</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Hydrocèle</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Hydrocele</s0><s5>06</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Hidrocele</s0><s5>06</s5></fC03><fC03 i1="07" i2="X" l="FRE"><s0>Campagne de masse</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="ENG"><s0>Mass campaign</s0><s5>09</s5></fC03><fC03 i1="07" i2="X" l="SPA"><s0>Campaña de población</s0><s5>09</s5></fC03><fC03 i1="08" i2="X" l="FRE"><s0>Prévalence</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="ENG"><s0>Prevalence</s0><s5>10</s5></fC03><fC03 i1="08" i2="X" l="SPA"><s0>Prevalencia</s0><s5>10</s5></fC03><fC03 i1="09" i2="X" l="FRE"><s0>Chronique</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="ENG"><s0>Chronic</s0><s5>11</s5></fC03><fC03 i1="09" i2="X" l="SPA"><s0>Crónico</s0><s5>11</s5></fC03><fC03 i1="10" i2="X" l="FRE"><s0>Sud</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="ENG"><s0>South</s0><s5>12</s5></fC03><fC03 i1="10" i2="X" l="SPA"><s0>Sur</s0><s5>12</s5></fC03><fC03 i1="11" i2="X" l="FRE"><s0>Inde</s0><s2>NG</s2><s5>13</s5></fC03><fC03 i1="11" i2="X" l="ENG"><s0>India</s0><s2>NG</s2><s5>13</s5></fC03><fC03 i1="11" i2="X" l="SPA"><s0>India</s0><s2>NG</s2><s5>13</s5></fC03><fC03 i1="12" i2="X" l="FRE"><s0>Médicament</s0><s5>14</s5></fC03><fC03 i1="12" i2="X" l="ENG"><s0>Drug</s0><s5>14</s5></fC03><fC03 i1="12" i2="X" l="SPA"><s0>Medicamento</s0><s5>14</s5></fC03><fC03 i1="13" i2="X" l="FRE"><s0>Médecine tropicale</s0><s5>15</s5></fC03><fC03 i1="13" i2="X" l="ENG"><s0>Tropical medicine</s0><s5>15</s5></fC03><fC03 i1="13" i2="X" l="SPA"><s0>Medicina tropical</s0><s5>15</s5></fC03><fC03 i1="14" i2="X" l="FRE"><s0>Antiparasitaire</s0><s5>25</s5></fC03><fC03 i1="14" i2="X" l="ENG"><s0>Parasiticide</s0><s5>25</s5></fC03><fC03 i1="14" i2="X" l="SPA"><s0>Antiparasitario</s0><s5>25</s5></fC03><fC03 i1="15" i2="X" l="FRE"><s0>Anthelminthique</s0><s5>26</s5></fC03><fC03 i1="15" i2="X" l="ENG"><s0>Anthelmintic</s0><s5>26</s5></fC03><fC03 i1="15" i2="X" l="SPA"><s0>Antihelmíntico</s0><s5>26</s5></fC03><fC03 i1="16" i2="X" l="FRE"><s0>Epanchement</s0><s5>27</s5></fC03><fC03 i1="16" i2="X" l="ENG"><s0>Effusion</s0><s5>27</s5></fC03><fC03 i1="16" i2="X" l="SPA"><s0>Derrame</s0><s5>27</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Nématodose</s0></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Nematode disease</s0></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Nematodosis</s0></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Helminthiase</s0></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Helminthiasis</s0></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Helmintiasis</s0></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Parasitose</s0></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Parasitosis</s0></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Parasitosis</s0></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Asie</s0><s2>NG</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Asia</s0><s2>NG</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Asia</s0><s2>NG</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Lactone</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Lactone</s0><s5>37</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Lactona</s0><s5>37</s5></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Macrocycle</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Macrocycle</s0><s5>38</s5></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Macrociclo</s0><s5>38</s5></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Pathologie des vaisseaux lymphatiques</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0><s5>39</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Linfático patología</s0><s5>39</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Cardiovascular disease</s0><s5>40</s5></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0><s5>40</s5></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Male genital diseases</s0><s5>41</s5></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Aparato genital macho patología</s0><s5>41</s5></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Pathologie du testicule</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Testicular diseases</s0><s5>42</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Testículo patología</s0><s5>42</s5></fC07><fN21><s1>147</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 08-0227645 INIST</NO><ET>Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India</ET><AU>YUVARAJ (J.); PANI (S. P.); VANAMAIL (P.); RAMAIAH (K. D.); DAS (P. K.)</AU><AF>Vector Control Research Centre/Pondicherry/Inde (1 aut., 2 aut., 3 aut., 4 aut., 5 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>TM & IH. Tropical medicine & international health; ISSN 1360-2276; Royaume-Uni; Da. 2008; Vol. 13; No. 5; Pp. 737-742; Bibl. 1/2 p.</SO><LA>Anglais</LA><EA>OBJECTIVE To evaluate the impact of seven rounds of mass administration of diethylcarbamazine (DEC) and ivermectin on the prevalence of chronic lymphatic filariasis and to compare it with that observed in a placebo arm in a community-level trial. METHODS Cross-sectional clinical surveys were carried out before and after seven rounds of mass drug administration (MDA). About 54-75% of the target population were treated at each round of MDA. RESULTS After seven rounds, the hydrocele prevalence had declined from the pre-intervention level of 20.5-5.1% (P < 0.05) in the DEC arm, from 23.9% to 10.4% (P < 0.05) in the ivermectin arm and from 20.4% to 10.9% (P < 0.05) in the placebo arm, equivalent to reductions of 75.3%, 56.6% and 46.6%, respectively. The lymphoedema/elephantiasis prevalence declined only marginally and without statistical significance from 3.7% to 3.2%, 4.6% to 3.9% and 2.9% to 2.3% in the DEC, ivermectin and placebo arm. After the seventh MDA, none of the sampled people in the 0-20 age group was found with hydrocele and there was a statistically significant decline in hydrocele prevalence in all other age groups in the communities treated with DEC, the drug known to have macrofilaricidal effect. The impact was relatively less in ivermectin arm. CONCLUSION Repeated DEC administration has the potential to prevent incidence of new hydrocele cases and may resolve the manifestation at least in a proportion of affected people. Apart from reducing the microfilaraemia prevalence and transmission of infection, MDA also results in significant public health benefits by reducing the burden of hydrocele in treated communities.</EA><CC>002B01; 002B05E03B4D; 002B12B04</CC><FD>Diéthylcarbamazine; Ivermectine; Filariose lymphatique; Maladie chronique; Lymphoedème; Hydrocèle; Campagne de masse; Prévalence; Chronique; Sud; Inde; Médicament; Médecine tropicale; Antiparasitaire; Anthelminthique; Epanchement</FD><FG>Nématodose; Helminthiase; Parasitose; Infection; Asie; Lactone; Macrocycle; Pathologie des vaisseaux lymphatiques; Pathologie de l'appareil circulatoire; Pathologie de l'appareil génital mâle; Pathologie du testicule</FG><ED>Diethylcarbamazine; Ivermectin; Lymphatic filariasis; Chronic disease; Lymphedema; Hydrocele; Mass campaign; Prevalence; Chronic; South; India; Drug; Tropical medicine; Parasiticide; Anthelmintic; Effusion</ED><EG>Nematode disease; Helminthiasis; Parasitosis; Infection; Asia; Lactone; Macrocycle; Lymphatic vessel disease; Cardiovascular disease; Male genital diseases; Testicular diseases</EG><SD>Dietilcarbamazina; Ivermectina; Filariasis linfática; Enfermedad crónica; Linfedema; Hidrocele; Campaña de población; Prevalencia; Crónico; Sur; India; Medicamento; Medicina tropical; Antiparasitario; Antihelmíntico; Derrame</SD><LO>INIST-26295.354000172757520170</LO><ID>08-0227645</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000401 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000401 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:08-0227645
|texte= Impact of seven rounds of mass administration of diethylcarbamazine and ivermectin on prevalence of chronic lymphatic filariasis in south India
}}
| This area was generated with Dilib version V0.6.31. |  |